LONDON, June 10 (Reuters)
GlaxoSmithKline stepped up its drive into emerging markets on Thursday with the acquisition of Argentina's Laboratorios Phoenix for $253 million.
The cash transaction -- the latest in a string of deals in developing markets -- gives the British-based drugmaker a portfolio of branded generics covering therapeutic areas such as cardiovascular, gastroenterology, metabolic and urology.
Phoenix also brings Glaxo a factory near Buenos Aires, a primary care sales force and pipeline of additional branded generic medicines. (Reporting by Ben Hirschler; editing by Paul Sandle)
Más
No hay comentarios:
Publicar un comentario